Area of research
Epidemiology · Hepatology
Research interest
Research focused on Placebo and Cirrhosis, with related work in Randomized controlled trial, Benzbromarone, Portal venous pressure. Notable publications include 'A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis', 'Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney', and 'Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease'.
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo
Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney